GTx, Inc. (NASDAQ:GTXI)’s share price hit a new 52-week low during mid-day trading on Thursday . The company traded as low as $1.30 and last traded at $1.33, with a volume of 5922 shares trading hands. The stock had previously closed at $1.35.
Several research firms have weighed in on GTXI. BidaskClub upgraded shares of GTX from a “sell” rating to a “hold” rating in a report on Friday, August 17th. Zacks Investment Research downgraded shares of GTX from a “buy” rating to a “hold” rating in a report on Wednesday, November 21st. ValuEngine downgraded shares of GTX from a “buy” rating to a “hold” rating in a report on Saturday, September 22nd. Stifel Nicolaus downgraded shares of GTX from a “buy” rating to a “hold” rating in a report on Friday, September 21st. Finally, Robert W. Baird downgraded shares of GTX from an “outperform” rating to a “neutral” rating and set a $17.00 target price for the company. in a report on Friday, September 21st. Five analysts have rated the stock with a hold rating, The company presently has an average rating of “Hold” and a consensus target price of $21.25.
The firm has a market cap of $32.47 million, a price-to-earnings ratio of -0.75 and a beta of 1.60.
GTX (NASDAQ:GTXI) last posted its earnings results on Thursday, November 15th. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.30) by ($0.09). Equities analysts predict that GTx, Inc. will post -1.65 earnings per share for the current fiscal year.
A number of large investors have recently bought and sold shares of GTXI. Bridgeway Capital Management Inc. purchased a new position in GTX during the 3rd quarter valued at about $431,000. Candriam Luxembourg S.C.A. acquired a new stake in shares of GTX during the 3rd quarter worth about $410,000. BlackRock Inc. boosted its stake in shares of GTX by 129.5% during the 2nd quarter. BlackRock Inc. now owns 390,150 shares of the biopharmaceutical company’s stock worth $5,973,000 after purchasing an additional 220,114 shares during the last quarter. Vivo Capital LLC acquired a new stake in shares of GTX during the 3rd quarter worth about $165,000. Finally, Vanguard Group Inc. boosted its stake in shares of GTX by 19.3% during the 3rd quarter. Vanguard Group Inc. now owns 467,463 shares of the biopharmaceutical company’s stock worth $734,000 after purchasing an additional 75,539 shares during the last quarter. Hedge funds and other institutional investors own 12.34% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This report was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this report on another site, it was copied illegally and reposted in violation of international trademark and copyright law. The correct version of this report can be read at https://www.dispatchtribunal.com/2018/12/07/gtx-gtxi-reaches-new-1-year-low-at-1-30.html.
About GTX (NASDAQ:GTXI)
GTx, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of medicines for the treatment of stress urinary incontinence (SUI) and prostate cancer. It focuses on the development of selective androgen receptor modulators (SARMs) for the treatment of breast cancer, SUI, and Duchenne muscular dystrophy; and selective androgen receptor degraders to treat progressive castration-resistant prostate cancer.
Further Reading: Short Selling – Explanation For Shorting Stocks
Receive News & Ratings for GTX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GTX and related companies with MarketBeat.com's FREE daily email newsletter.